
Cardiol Therapeutics Inc. (NASDAQ:CRDL – Free Report) – Equities researchers at Brookline Capital Markets issued their FY2026 earnings estimates for Cardiol Therapeutics in a research note issued to investors on Monday, November 16th. Brookline Capital Markets analyst F. Ahmed expects that the company will earn ($0.25) per share for the year. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.20) per share. Brookline Capital Markets also issued estimates for Cardiol Therapeutics’ Q4 2026 earnings at ($0.07) EPS.
Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02).
View Our Latest Research Report on Cardiol Therapeutics
Cardiol Therapeutics Price Performance
CRDL stock opened at $0.86 on Thursday. Cardiol Therapeutics has a one year low of $0.84 and a one year high of $2.34. The firm has a 50 day simple moving average of $1.30 and a two-hundred day simple moving average of $1.30.
Institutional Investors Weigh In On Cardiol Therapeutics
A number of large investors have recently added to or reduced their stakes in the company. Parallel Advisors LLC bought a new position in shares of Cardiol Therapeutics during the third quarter valued at about $32,000. Royal Bank of Canada boosted its holdings in shares of Cardiol Therapeutics by 62.3% during the first quarter. Royal Bank of Canada now owns 21,648 shares of the company’s stock worth $29,000 after purchasing an additional 8,306 shares during the period. Virtu Financial LLC purchased a new stake in shares of Cardiol Therapeutics during the third quarter worth about $42,000. Concurrent Investment Advisors LLC purchased a new stake in shares of Cardiol Therapeutics during the second quarter worth about $27,000. Finally, Cibc World Market Inc. bought a new stake in shares of Cardiol Therapeutics in the third quarter worth about $55,000. Institutional investors own 12.49% of the company’s stock.
Cardiol Therapeutics Company Profile
Cardiol Therapeutics is a Canadian biotechnology company developing therapies for inflammatory heart disease and other cardiovascular conditions. Its research focuses on treatments intended to address inflammation and related damage to the heart. The company’s lead candidate, CardiolRx, is a pharmaceutical-grade cannabidiol formulation under clinical investigation for conditions including myocarditis and pericarditis. Cardiol also has CRD-38, an investigational candidate being studied for potential use in heart failure.
Recommended Stories
- Five stocks we like better than Cardiol Therapeutics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
